Diffusion-weighted magnetic resonance imaging in non-invasive monitoring of antiangiogenic therapy in experimental tumor model

• Published in: Experimental Oncology
• Date: 2010
• Main Authors: Kharuzhyk, S.A., Petrovskaya, N.A., Vosmitel, M.A.
• Format: Article
• Language: English
• Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2010
• Subjects: Short communications
• Online Access: https://nasplib.isofts.kiev.ua/handle/123456789/138599
• Journal Title: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Cite this: Diffusion-weighted magnetic resonance imaging in non-invasive monitoring of antiangiogenic therapy in experimental tumor model / S.A. Kharuzhyk, N.A. Petrovskaya, M.A. Vosmitel // Experimental Oncology. — 2010. — Т. 32, № 2. — С. 104-106. — Бібліогр.: 7 назв. — англ.

Aim: To show usefulness of diffusion-weighted magnetic resonance imaging (MRI) for non-invasive assessment of experimental tumor after antiangiogenic treatment. Methods: M1 sarcoma was implanted to the peritoneal cavity of the rat and allowed to grow to a palpable tumor size. Animal was treated with a single injection of endothelial growth factor antibody Bevacizumab (Avastin). Serial MRI scanning including diffusion-weighted sequence was performed before and up to 100 h after treatment. Animal was sacrificed thereafter and MRI data were correlated with morphology. Results: Apparent diffusion coefficient (ADC) maps derived tumor necrotic area correlated well with histology-derived tumor necrotic area. ADC threshold of 1.39 × 10–3 mm2/s appeared to be optimal for tumor necrosis quantification in this tumor model and allowed to follow temporal changes of tumor internal structure after treatment. Conclusion: Diffusion-weighted MRI permits non-invasive tissue characterization without the need for exogenous contrast agents and, therefore, may be used to individualise therapy and to monitor tumor response.